Table 2.
Primary and secondary outcomes at baseline and 6-month follow-up of PROGRESS
| Variable | Intent-to-treat | As-treated | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | |||||
| PROGRESS M (SD) |
Enhanced Usual Care M (SD) |
PROGRESS M (SD) |
Enhanced Usual Care M (SD) |
Used PROGRESS M (SD) |
Did not use PROGRESS M (SD) |
Used PROGRESS M (SD) |
Did not use PROGRESS M (SD) |
|
| Primary Outcomes | ||||||||
| Cancer coping total score | 2.22 (0.64) | 2.22 (0.67) | 2.22 (0.63) | 2.17 (0.64) | 2.16 (0.71) | 2.24 (0.67) | 2.14 (0.60) | 2.22 (0.65) |
| General coping techniques | 1.88 (0.70) | 1.88 (0.70) | 1.93 (0.73) | 1.91 (0.73) | 1.78 (0.65) | 1.90 (0.71) | 1.84 (0.74) | 1.95 (0.72) |
| Diversion | 2.00 (0.81) | 2.03 (0.84) | 2.08 (0.81) | 2.04 (0.78) | 1.90 (0.82) | 2.04 (0.83) | 1.94 (0.75) | 2.10 (0.81) |
| Planning | 2.51 (0.96) | 2.50 (0.91) | 2.52 (0.85) | 2.43 (0.87) | 2.41 (0.98) | 2.53 (0.92) | 2.42 (0.86) | 2.49 (0.86) |
| Positive outlook | 2.74 (0.78) | 2.70 (0.85) | 2.52 (0.64) | 2.50 (0.64) | 2.80 (0.75) | 2.70 (0.83) | 2.52 (0.62) | 2.51 (0.64) |
| Interpersonal | 1.94 (0.78) | 2.06 (0.88) | 1.80 (0.76) | 1.88 (0.80) | 1.89 (0.74) | 2.03 (0.85) | 1.81 (0.82) | 1.85 (0.77) |
| Urinary incontinence | 63.43 (29.67) | 62.57 (30.14) | 78.54 (22.30) | 76.72 (23.16) | 66.83 (30.99) | 62.04 (29.55) | 79.46 (22.98) | 76.88 (22.63) |
| Urinary irritation | 78.51 (19.02) | 79.49 (19.37) | 87.44 (15.14) | 88.82 (12.70) | 79.71 (17.91) | 78.81 (19.50) | 86.29 (15.95) | 88.88 (13.02) |
| Bowel dysfunction | 88.66 (15.81) | 89.76 (14.41) | 92.62 (13.30) | 91.41 (13.08) | 90.26 (13.55) | 88.94 (15.51) | 92.21 (12.72) | 91.92 (13.39) |
| Sexual dysfunction | 32.14 (29.24) | 31.44 (29.68) | 34.19 (29.38) | 36.39 (28.42) | 34.15 (30.35) | 31.21 (29.20) | 35.64 (31.24) | 35.16 (27.94) |
| Secondary Outcomes | ||||||||
| Self-efficacy for re-entry | 8.75 (1.11) | 8.82 (1.11) | 8.54 (1.15) | 8.48 (1.19) | 8.82 (0.98) | 8.77 (1.14) | 8.62 (1.18) | 8.47 (1.16) |
| Self-efficacy for symptom control | 3.33 (0.48) | 3.32 (0.51) | 3.36 (0.44) | 3.32 (0.52) | 3.39 (0.42) | 3.31 (0.51) | 3.38 (0.44) | 3.32 (0.49) |
| Practical concerns | 2.41 (0.99) | 2.45 (1.01) | 1.58 (0.86) | 1.68 (0.92) | 2.36 (0.97) | 2.45 (1.00) | 1.45 (0.80) | 1.70 (0.91) |
| Medical interactions | 2.70 (3.28) | 2.39 (3.07) | 2.09 (2.20) | 1.96 (2.72) | 2.23 (2.50) | 2.63 (3.32) | 1.72 (1.82) | 2.14 (2.68) |
| Marital interactions | 3.40 (3.92) | 3.42 (3.97) | 3.34 (3.93) | 3.18 (4.18) | 3.14 (3.34) | 3.48 (4.07) | 2.87 (4.09) | 3.41 (4.05) |
Note: No significant differences between groups at baseline or 6-month follow-up.